Pendetide
From Self-sufficiency
| Pendetide | |
|---|---|
| File:Pendetide structure.svg | |
| N6-[N-[2-[[2-[Bis(carboxymethyl)amino]ethyl](carboxymethyl)amino]ethyl]-N-(carboxymethyl)glycyl]-N2-(N-glycyl-L-tyrosyl)-L-lysine | |
| style="background: #F8EABA; text-align: center;" colspan="2" | Identifiers | |
| CAS number | 148805-91-8 |
| style="background: #F8EABA; text-align: center;" colspan="2" | Properties | |
| Molecular formula | C31H47N7O14 |
| Molar mass | 741.318 g/mol |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) | |
| Infobox references | |
Pendetide (GYK-DTPA) is a chelating agent. It consists of pentetic acid (DTPA) linked to the tripeptide glycine (G) – L-tyrosine (Y) – L-lysine (K).[1]
Use
The following monoclonal antibodies are linked to pendetide to chelate a radionuclide, indium-111. The antibodies selectively bind to certain tumour cells, and the radioactivity is then used for imaging of the tumours.
- Indium (111In) capromab pendetide (prostate cancer)
- Indium (111In) satumomab pendetide (other cancer types)
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
 |
This pharmacology-related article is a stub. You can help ssf by expanding it. |
